Melinta Therapeutics, Inc. News Releases http://ir.melinta.com/ Melinta Therapeutics, Inc. News Releases en Melinta Therapeutics Reports First Quarter 2019 Financial Results and Provides Corporate Update http://ir.melinta.com/news-releases/news-release-details/melinta-therapeutics-reports-first-quarter-2019-financial ~ Revenue of $14.1 million , Including Net Product Sales of $11.8 million , for the First Quarter 2019 ~ ~ Reduction of Operating Expenses of 34 Percent, or $19.8 million , Year-Over-Year ~ ~ Filed Supplemental New Drug Application for Baxdela ® (delafloxacin)  for the Treatment of Thu, 09 May 2019 16:00:00 -0400 Melinta Therapeutics, Inc. News Releases 12471 Melinta Therapeutics to Present at Making a Difference in Infectious Diseases (MAD-ID) 2019 Annual Meeting http://ir.melinta.com/news-releases/news-release-details/melinta-therapeutics-present-making-difference-infectious MORRISTOWN, N.J. , May 07, 2019 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ: MLNT), a commercial-stage company focused on the development and commercialization of novel antibiotics to treat serious bacterial infections, announced today that it will present data on its portfolio, Tue, 07 May 2019 07:30:00 -0400 Melinta Therapeutics, Inc. News Releases 12466 Melinta Therapeutics to Report First Quarter 2019 Financial Results on May 9, 2019 http://ir.melinta.com/news-releases/news-release-details/melinta-therapeutics-report-first-quarter-2019-financial-results MORRISTOWN, N.J. , May 02, 2019 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ: MLNT), a commercial-stage company focused on the development and commercialization of novel antibiotics to treat serious bacterial infections, today announced it intends to release its first quarter 2019 Thu, 02 May 2019 16:30:00 -0400 Melinta Therapeutics, Inc. News Releases 12456 Melinta Therapeutics Announces Multiple Presentations at the 29th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) http://ir.melinta.com/news-releases/news-release-details/melinta-therapeutics-announces-multiple-presentations-29th ~  Presentations and Posters Highlight New Data from Antibiotics Portfolio ~ MORRISTOWN, N.J. , April 08, 2019 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ: MLNT), a commercial-stage company focused on the development and commercialization of novel antibiotics to treat serious bacterial Mon, 08 Apr 2019 07:30:00 -0400 Melinta Therapeutics, Inc. News Releases 12441 Melinta Therapeutics Reports Fourth Quarter and Full-Year 2018 Financial Results http://ir.melinta.com/news-releases/news-release-details/melinta-therapeutics-reports-fourth-quarter-and-full-year-2018 ~ Reports Revenue of $96.4 million , Including Net Product Sales of $46.6 million , for the Full-Year 2018 ~ ~ Net Product Sales of $14.6 million for the Fourth Quarter of 2018, up 32 Percent from Prior Quarter ~ ~ Corporate Milestones Across Commercial Operations, Clinical and Business Development Wed, 13 Mar 2019 16:00:00 -0400 Melinta Therapeutics, Inc. News Releases 12421 Melinta Therapeutics to Report Fourth Quarter and Year-End 2018 Financial Results on March 13, 2019 http://ir.melinta.com/news-releases/news-release-details/melinta-therapeutics-report-fourth-quarter-and-year-end-2018 MORRISTOWN, N.J. , March 05, 2019 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ: MLNT), a commercial-stage company focused on the development and commercialization of novel antibiotics to treat serious bacterial infections, today announced it intends to release its fourth quarter and Tue, 05 Mar 2019 08:00:00 -0500 Melinta Therapeutics, Inc. News Releases 12416 Melinta Therapeutics Announces Closing of Initial $75 Million Vatera Convertible Loan Funding http://ir.melinta.com/news-releases/news-release-details/melinta-therapeutics-announces-closing-initial-75-million-vatera – Amendment to Deerfield Facility Agreement Becomes Effective – – John H. Johnson Appointed Permanent Chief Executive Officer – – Company to Report Fourth Quarter and Full Year 2018 Financial Results on March 13, 2019 – MORRISTOWN, N.J. , Feb. 25, 2019 (GLOBE NEWSWIRE) --   Melinta Therapeutics, Mon, 25 Feb 2019 08:15:00 -0500 Melinta Therapeutics, Inc. News Releases 12391 Melinta Therapeutics Announces One-for-Five Reverse Stock Split http://ir.melinta.com/news-releases/news-release-details/melinta-therapeutics-announces-one-five-reverse-stock-split NEW HAVEN, Conn. , Feb. 21, 2019 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ: MLNT), a commercial-stage company focused on the development and commercialization of novel antibiotics to treat serious bacterial infections, today announced that its Board of Directors has approved a Thu, 21 Feb 2019 13:30:00 -0500 Melinta Therapeutics, Inc. News Releases 12371 Melinta Therapeutics Provides Corporate Updates http://ir.melinta.com/news-releases/news-release-details/melinta-therapeutics-provides-corporate-updates ~ Highlights Continued Positive Sales Momentum and Estimated Year-End Cash Position ~ ~ Confirms Previously Announced Cost Savings Guidance ~   ~ Continues Senior Leadership Team Evolution with New Management Appointments ~ NEW HAVEN, Conn. , Feb. 04, 2019 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Mon, 04 Feb 2019 08:00:00 -0500 Melinta Therapeutics, Inc. News Releases 12336 John H. Johnson Agrees to Become Permanent Chief Executive Officer of Melinta Therapeutics http://ir.melinta.com/news-releases/news-release-details/john-h-johnson-agrees-become-permanent-chief-executive-officer NEW HAVEN, Conn. , Dec. 19, 2018 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ: MLNT), a commercial-stage company developing and commercializing novel antibiotics to treat serious bacterial infections, today announced that John H. Johnson has agreed to become the permanent chief executive Wed, 19 Dec 2018 08:31:00 -0500 Melinta Therapeutics, Inc. News Releases 12246